Page 175 - 2019_02-Haematologica-web

Outcome in MM after allo-SCT
Transplant. 2016;51(4):492-500.
5. Sobh M, Michallet M, Gahrton G, et al.
Allogeneic hematopoietic cell transplanta- tion for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia. 2016; 30(10):2047-2054.
6. Gahrton G, Svensson H, Cavo M, et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001;113(1):209-216.
7. Maloney DG. Allografting with nonmye- loablative conditioning following cytore- ductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102(9):3447-3454.
8. Gahrton G, Iacobelli S, Bjorkstrand B, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long- term results of the EBMT-NMAM2000 study. Blood. 2013;121(25):5055-5063.
9. Giaccone L, Storer B, Patriarca F, et al. Long- term follow-up of a comparison of non- myeloablative allografting with autograft- ing for newly diagnosed myeloma. Blood. 2011;117(24):6721-6727.
10. Garban F. Prospective comparison of autol- ogous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell trans- plantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006; 107(9):3474-3480.
11. Moreau P, Garban F, Attal M, et al. Long- term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloabla- tive allotransplantation with autologous transplantation in high-risk de novo multi- ple myeloma. Blood. 2008; 112(9):3914- 3915.
12. Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diag- nosed multiple myeloma. Blood. 2008; 112(9):3591-3593.
13. Lokhorst HM, van der Holt B, Cornelissen JJ, et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood. 2012; 119(26):6219- 6225.
14. Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell trans- plantation followed by allogeneic or autol- ogous haemopoietic stem-cell transplanta- tion in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011; 12(13):1195-1203.
15. de Lavallade H, El-Cheikh J, Faucher C, et al. Reduced-intensity conditioning allo- geneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant. 2008;41(11):953-960.
16. Mehta J, Tricot G, Jagannath S, et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant. 1998;21(9):887-892.
17. Qazilbash MH, Saliba R, De Lima M, et al. Second autologous or allogeneic transplan- tation after the failure of first autograft in patients with multiple myeloma. Cancer. 2006;106(5):1084-1089.
18. Patriarca F, Einsele H, Spina F, et al. Allogeneic stem cell transplantation in nul- tiple myeloma relapsed after Autograft: a multicenter retrospective study based on donor availability. Biol Blood Marrow Transplant. 2012;18(4):617-626.
19. Patriarca F, Bruno B, Einsele H, et al. Long- Term Follow-Up of a Donor versus No- Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation. Biol Blood Marrow Transplant. 2018;24(2):406- 409.
20. Lokhorst HM. The occurrence of graft-ver- sus-host disease is the major predictive fac- tor for response to donor lymphocyte infu- sions in multiple myeloma. Blood. 2004; 103(11):4362-4364.
21. Kröger N, Badbaran A, Lioznov M, et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol. 2009;37(7):791-798.
22. Zojer N, Königsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridiza- tion. Blood. 2000;95(6):1925-1930.
23. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-e548.
24. Engelhardt M, Domm A-S, Dold SM, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910- 921.
25. Engelhardt M, Dold SM, Ihorst G, et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016; 101(9):1110-1119.
26. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophy- laxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855-864.
27. Aalen OO, Johansen S. An empirical transi- tion matrix for non-homogeneous Markov chains based on censored observations. Scand J Stat. 1978;5(3):141-150.
28. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc. 1999; 94(446):496-509.
29. Chng WJ, Dispenzieri A, Chim C-S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014; 28(2):269-277.
30. Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high- risk cytogenetics: a consensus of the International Myeloma Working Group.
Blood. 2016;127(24):2955-2962.
31. Garderet L, Iacobelli S, Koster L, et al. Outcome of a salvage third autologous stem cell transplantation in multiple myelo- ma. Biol Blood Marrow Transplant.
2018;24(7):1372-1378.
32. Rasche L, Röllig C, Stuhler G, et al.
Allogeneic hematopoietic cell transplanta- tion in multiple myeloma: focus on longitu- dinal assessment of donor chimerism, extramedullary disease, and high-risk cyto- genetic features. Biol Blood Marrow Transplant. 2016;22(11):1988-1996.
33. Björkstrand B, Iacobelli S, Hegenbart U, et al. Tandem autologous/Reduced-Intensity Conditioning allogeneic stem-cell trans- plantation versus autologous transplanta- tion in myeloma: long-term follow-up. J Clin Oncol. 2011; 29(22):3016-3022.
34. Kröger N, Badbaran A, Zabelina T, et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplanta- tion in patients with multiple myeloma. Biol Blood Marrow Transplant. 2013; 19(3):398-404.
35. Gay F, Engelhardt M, Terpos E, et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspec- tives. Haematologica. 2018;103(2):197-211.
36. Bruno B, Rotta M, Patriarca F, et al. A com- parison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356(11):1110-1120.
37. Auner HW, Szydlo R, van Biezen A, et al. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2013;48(11):1395-1400.
38. Wirk B, Byrne M, Dai Y, Moreb JS. Outcomes of salvage autologous versus allo- geneic hematopoietic cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell transplanta- tion. J Clin Med Res. 2013; 5(3):174-184.
39. Freytes CO, Vesole DH, LeRademacher J, et al. Second transplants for multiple myelo- ma relapsing after a previous autotrans- plant-reduced-intensity allogeneic vs autol- ogous transplantation. Bone Marrow Transplant. 2014;49(3):416-421.
40. Einsele H, Schäfer H-J, Hebart H, et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol. 2003;121(3):411-418.
41. Köhler M, Greil C, Hudecek M, et al. Current developments in immunotherapy in the treatment of multiple myeloma. Cancer. 2018;124(10):2075-2085.
42. Giaccone L, Evangelista A, Patriarca F, et al. Impact of new drugs on the long-term fol- low-up of upfront tandem autograft-allo- graft in multiple myeloma. Biol Blood Marrow Transplant. 2018;24(1):189-193.
43. Htut M, D’Souza A, Krishnan A, et al. Autologous/allogeneic hematopoietic cell transplantation versus tandem autologous transplantation for multiple myeloma: comparison of long-term postrelapse sur- vival. Biol Blood Marrow Transplant. 2018; 24(3):478-485.
haematologica | 2019; 104(2)
379